MiMedx Group Tidigare resultatutveckling
Tidigare kriterier kontrolleras 2/6
MiMedx Group har ökat intäkterna med en genomsnittlig årlig takt på 61.9%, medan Biotechs -branschen såg intäkterna växer på 36.2% årligen. Intäkterna har varit växande med en genomsnittlig takt på 10.8% per år. MiMedx Group s avkastning på eget kapital är 12.6% och den har en nettomarginal på 7.9%.
Viktig information
61.86%
Tillväxttakt i vinsten
62.12%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | 10.81% |
| Avkastning på eget kapital | 12.64% |
| Nettomarginal | 7.88% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaUppdatering av berättelse • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Ny berättelse • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
Ny berättelse • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Uppdatering av berättelse • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Uppdatering av berättelse • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Uppdatering av berättelse • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Uppdatering av berättelse • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Uppdatering av berättelse • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Analysartikel • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Analysartikel • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Analysartikel • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analysartikel • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Analysartikel • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Ny berättelse • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Analysartikel • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analysartikel • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur MiMedx Group tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 389 | 31 | 259 | 16 |
| 31 Dec 25 | 419 | 49 | 266 | 15 |
| 30 Sep 25 | 393 | 41 | 254 | 14 |
| 30 Jun 25 | 364 | 32 | 239 | 13 |
| 31 Mar 25 | 352 | 40 | 221 | 13 |
| 31 Dec 24 | 349 | 42 | 216 | 12 |
| 30 Sep 24 | 343 | 79 | 210 | 11 |
| 30 Jun 24 | 340 | 79 | 209 | 11 |
| 31 Mar 24 | 335 | 68 | 216 | 12 |
| 31 Dec 23 | 321 | 56 | 216 | 13 |
| 30 Sep 23 | 309 | 19 | 215 | 6 |
| 30 Jun 23 | 295 | 2 | 219 | 8 |
| 31 Mar 23 | 281 | -18 | 225 | 10 |
| 31 Dec 22 | 268 | -27 | 221 | 13 |
| 30 Sep 22 | 261 | -34 | 216 | 22 |
| 30 Jun 22 | 256 | -28 | 209 | 20 |
| 31 Mar 22 | 258 | -19 | 202 | 19 |
| 31 Dec 21 | 242 | -18 | 199 | 10 |
| 30 Sep 21 | 260 | -35 | 223 | 16 |
| 30 Jun 21 | 261 | -83 | 233 | 15 |
| 31 Mar 21 | 246 | -88 | 231 | 13 |
| 31 Dec 20 | 248 | -83 | 240 | 12 |
| 30 Sep 20 | 256 | -73 | 212 | 11 |
| 30 Jun 20 | 281 | -8 | 210 | 10 |
| 31 Mar 20 | 294 | -17 | 233 | 11 |
| 31 Dec 19 | 299 | -26 | 265 | 11 |
| 30 Sep 19 | 315 | -54 | 270 | 13 |
| 30 Jun 19 | 314 | -67 | 287 | 14 |
| 31 Mar 19 | 342 | -48 | 295 | 15 |
| 31 Dec 18 | 359 | -30 | 295 | 16 |
| 30 Sep 18 | 354 | 41 | 275 | 15 |
| 30 Jun 18 | 352 | 59 | 260 | 16 |
| 31 Mar 18 | 333 | 65 | 235 | 17 |
| 31 Dec 17 | 321 | 65 | 220 | 18 |
| 30 Sep 17 | 303 | 35 | 216 | 18 |
| 30 Jun 17 | 283 | 21 | 205 | 15 |
| 31 Mar 17 | 264 | 15 | 192 | 14 |
| 31 Dec 16 | 222 | 0 | 172 | 14 |
| 30 Sep 16 | 227 | 20 | 168 | 11 |
| 30 Jun 16 | 212 | 23 | 154 | 10 |
| 31 Mar 16 | 200 | 27 | 144 | 9 |
| 31 Dec 15 | 187 | 29 | 133 | 8 |
| 30 Sep 15 | 175 | 20 | 126 | 8 |
| 30 Jun 15 | 160 | 17 | 115 | 8 |
Kvalitetsintäkter: MDXG har inkomster av hög kvalitet.
Växande vinstmarginal: MDXG s nuvarande netto vinstmarginaler (7.9%) är lägre än förra året (11.3%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: MDXG har blivit lönsamt under de senaste 5 åren och ökat intäkterna med 61.9% per år.
Accelererande tillväxt: MDXG s har haft negativ intäktstillväxt under det senaste året, så det kan inte jämföras med dess 5-åriga genomsnitt.
Resultat vs industri: MDXG hade negativ intäktstillväxt ( -23.2% ) under det senaste året, vilket gör det svårt att jämföra med branschens genomsnitt Biotechs ( 54.5% ).
Avkastning på eget kapital
Hög ROE: MDXG s avkastning på eget kapital ( 12.6% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/12 15:37 |
| Aktiekurs vid dagens slut | 2026/06/12 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
MiMedx Group, Inc. bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |